1887

Abstract

Newcastle disease virus (NDV) is being developed as an oncolytic virus for virotherapy. In this study we analysed the regulation of complement-mediated inactivation of a recombinant NDV in different host cells. NDV grown in human cells was less sensitive to complement-mediated virus inactivation than NDV grown in embryonated chicken eggs. Additionally, NDV produced from HeLa-S3 cells is more resistant to complement than NDV from 293F cells, which correlated with higher expression and incorporation of complement regulatory proteins (CD46, CD55 and CD59) into virions from HeLa-S3 cells. Further analysis of the recombinant NDVs individually expressing the three CD molecules showed that CD55 is the most potent in counteracting complement-mediated virus inactivation. The results provide important information on selecting NDV manufacture substrate to mitigate complement-mediated virus inactivation.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000498
2016-08-01
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/8/1765.html?itemId=/content/journal/jgv/10.1099/jgv.0.000498&mimeType=html&fmt=ahah

References

  1. Biswas M. , Johnson J. B. , Kumar S. R. , Parks G. D. , Elankumarana S. . ( 2012;). Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. . J Virol 86: 12708–12716. [CrossRef] [PubMed]
    [Google Scholar]
  2. Blue C. E. , Spiller O. B. , Blackbourn D. J. . ( 2004;). The relevance of complement to virus biology. . Virology 319: 176–184. [CrossRef] [PubMed]
    [Google Scholar]
  3. Buijs P. R. , Verhagen J. H. , van Eijck C. H. , van den Hoogen B. G. . ( 2015;). Oncolytic viruses: from bench to bedside with a focus on safety. . Hum Vaccin Immunother 11: 1573–1584. [CrossRef] [PubMed]
    [Google Scholar]
  4. Cassel W. A. , Garrett R. E. . ( 1965;). Newcastle disease virus as an antineoplastic agent. . Cancer 18: 863–868.[PubMed] [CrossRef]
    [Google Scholar]
  5. Cassel W. A. , Murray D. R. . ( 1992;). A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. . Med Oncol Tumor Pharmacother 9: 169–171.[PubMed]
    [Google Scholar]
  6. Cheng X. , Wang W. , Xu Q. , Harper J. , Carroll D. , Galinski M. S. , Suzich J. , Jin H . ( 2016;). Genetic modification of oncolytic Newcastle disease virus for cancer therapy. . J Virol 90: 5343–5352. [CrossRef] [PubMed]
    [Google Scholar]
  7. Chiocca E. A. , Rabkin S. D. . ( 2014;). Oncolytic viruses and their application to cancer immunotherapy. . Cancer Immunol Res 2: 295–300. [CrossRef] [PubMed]
    [Google Scholar]
  8. Cooper N. R. . ( 1991;). Complement evasion strategies of microorganisms. . Immunol Today 12: 327–331. [CrossRef] [PubMed]
    [Google Scholar]
  9. Coyne K. E. , Hall S. E. , Thompson S. , Arce M. A. , Kinoshita T. , Fujita T. , Anstee D. J. , Rosse W. , Lublin D. M. . ( 1992;). Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. . J Immunol 149: 2906–2913.[PubMed]
    [Google Scholar]
  10. Cummings K. L. , Waggoner S. N. , Tacke R. , Hahn Y. S. . ( 2007;). Role of complement in immune regulation and its exploitation by virus. . Viral Immunol 20: 505–524. [CrossRef] [PubMed]
    [Google Scholar]
  11. Huang Z. , Panda A. , Elankumaran S. , Govindarajan D. , Rockemann D. D. , Samal S. K. . ( 2004;). The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. . J Virol 78: 4176–4184.[PubMed] [CrossRef]
    [Google Scholar]
  12. Iwata K. , Seya T. , Yanagi Y. , Pesando J. M. , Johnson P. M. , Okabe M. , Ueda S. , Ariga H. , Nagasawa S. . ( 1995;). Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46. . J Biol Chem 270: 15148–15152.[PubMed] [CrossRef]
    [Google Scholar]
  13. Janeway C. A Jr , Travers P. , Walport M. , Shlomchik M. J. . ( 2001;). The immune system in health and disease. . Immunobiology, , 5th edn.. New York:: Garland Science;.
    [Google Scholar]
  14. Johnson J. B. , Lyles D. S. , Alexander-Miller M. A. , Parks G. D. . ( 2012;). Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. . J Virol 86: 9929–9940. [CrossRef] [PubMed]
    [Google Scholar]
  15. Laliberte J. P. , McGinnes L. W. , Peeples M. E. , Morrison T. G. . ( 2006;). Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles. . J Virol 80: 10652–10662. [CrossRef] [PubMed]
    [Google Scholar]
  16. Lambris J. D. , Ricklin D. , Geisbrecht B. V. . ( 2008;). Complement evasion by human pathogens. . Nat Rev Microbiol 6: 132–142. [CrossRef] [PubMed]
    [Google Scholar]
  17. Li L. , Spendlove I. , Morgan J. , Durrant L. G. . ( 2001;). CD55 is over-expressed in the tumour environment. . Br J Cancer 84: 80–86. [CrossRef] [PubMed]
    [Google Scholar]
  18. Liszewski M. K. , Leung M. K. , Atkinson J. P. . ( 1998;). Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. . J Immuno 161: 3711–3718.
    [Google Scholar]
  19. Liszewski M. K. , Fang C. J. , Atkinson J. P. . ( 2008;). Inhibiting complement activation on cells at the step of C3 cleavage. . Vaccine 26 Suppl 8: 122–127. [CrossRef] [PubMed]
    [Google Scholar]
  20. Markiewski M. M. , DeAngelis R. A. , Benencia F. , Ricklin-Lichtsteiner S. K. , Koutoulaki A. , Gerard C. , Coukos G. , Lambris J. D. . ( 2008;). Modulation of the antitumor immune response by complement. . Nat Immunol 9: 1225–1235. [CrossRef] [PubMed]
    [Google Scholar]
  21. Mazumdar B. , Kim H. , Meyer K. , Bose S. K. , Di Bisceglie A. M. , Ray R. B. , Diamond M. S. , Atkinson J. P. , Ray R. . ( 2013;). Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. . J Virol 87: 7902–7910. [CrossRef] [PubMed]
    [Google Scholar]
  22. Moore A. E. , Diamond L. C. , Mackay H. H. , Sabachewsky L. . ( 1952;). Influence of hemagglutinating viruses on tumor cell suspensions. II. Newcastle disease virus and Ehrlich carcinoma. . Proc Soc Exp Biol Med 81: 498–501.[PubMed] [CrossRef]
    [Google Scholar]
  23. Murray K. P. , Mathure S. , Kaul R. , Khan S. , Carson L. F. , Twiggs L. B. , Martens M. G. , Kaul A. . ( 2000;). Expression of complement regulatory proteins – CD 35, CD 46, CD 55, and CD 59 – in benign and malignant endometrial tissue. . Gynecol Oncol 76: 176–182. [CrossRef] [PubMed]
    [Google Scholar]
  24. Osuka F. , Endo Y. , Higuchi M. , Suzuki H. , Shio Y. , Fujiu K. , Kanno R. , Oishi A. , Terashima M. et al. ( 2006;). Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. . Genomics 88: 316–322. [CrossRef] [PubMed]
    [Google Scholar]
  25. Post T. W. , Liszewski M. K. , Adams E. M. , Tedja I. , Miller E. A. , Atkinson J. P. . ( 1991;). Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. . J Exp Med 174: 93–102.[PubMed] [CrossRef]
    [Google Scholar]
  26. Prince A. M. , Ginsberg H. S. . ( 1957a;). Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus–cell interaction. . J Immunol 79: 94–106.
    [Google Scholar]
  27. Prince A. M. , Ginsberg H. S. . ( 1957b;). Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. II. The mechanism and significance of in vitro recovery from the effect of NDV. . J Immunol 79: 107–112.
    [Google Scholar]
  28. Ren X. , Xue C. , Kong Q. , Zhang C. , Bi Y. , Cao Y. . ( 2012;). Proteomic analysis of purified Newcastle disease virus particles. . Proteome Sci 10: 32. [CrossRef] [PubMed]
    [Google Scholar]
  29. Ricklin D. , Hajishengallis G. , Yang K. , Lambris J. D. . ( 2010;). Complement: a key system for immune surveillance and homeostasis. . Nat Immunol 11: 785–797. [CrossRef] [PubMed]
    [Google Scholar]
  30. Rushmere N. K. , Knowlden J. M. , Gee J. M. , Harper M. E. , Robertson J. F. , Morgan B. P. , Nicholson R. I. . ( 2004;). Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. . Int J Cancer 108: 930–936. [CrossRef] [PubMed]
    [Google Scholar]
  31. Russell S. M. , Sparrow R. L. , McKenzie I. F. , Purcell D. F. . ( 1992;). Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. . Eur J Immunol 22: 1513–1518. [CrossRef] [PubMed]
    [Google Scholar]
  32. Saifuddin M. , Hedayati T. , Atkinson J. P. , Holguin M. H. , Parker C. J. , Spear G. T. . ( 1997;). Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. . J Gen Virol 78: 1907–1911. [CrossRef] [PubMed]
    [Google Scholar]
  33. Simon H. G. , Risse B. , Jost M. , Oppenheimer S. , Kari C. , Rodeck U. . ( 1996;). Identification of differentially expressed messenger RNAs in human melanocytes and melanoma cells. . Cancer Res 56: 3112–3117.[PubMed]
    [Google Scholar]
  34. Spear G. T. , Lurain N. S. , Parker C. J. , Ghassemi M. , Payne G. H. , Saifuddin M. . ( 1995;). Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). . J Immunol 155: 4376–4381.[PubMed]
    [Google Scholar]
  35. Stoermer K. A. , Morrison T. E. . ( 2011;). Complement and viral pathogenesis. . Virology 411: 362–373. [CrossRef] [PubMed]
    [Google Scholar]
  36. Vanderplasschen A. , Mathew E. , Hollinshead M. , Sim R. B. , Smith G. L. . ( 1998;). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. . Proc Natl Acad Sci U S A 95: 7544–7549.[PubMed] [CrossRef]
    [Google Scholar]
  37. Varela J. C. , Atkinson C. , Woolson R. , Keane T. E. , Tomlinson S. . ( 2008;). Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. . Int J Cancer 123: 1357–1363. [CrossRef] [PubMed]
    [Google Scholar]
  38. Zamarin D. , Palese P. . ( 2012;). Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. . Future Microbiol 7: 347–367. [CrossRef] [PubMed]
    [Google Scholar]
  39. Zipfel P. F. , Skerka C. . ( 2009;). Complement regulators and inhibitory proteins. . Nat Rev Immunol 9: 729–740. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000498
Loading
/content/journal/jgv/10.1099/jgv.0.000498
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error